Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092387 - SELF REPLICATING RNA SYSTEM

Publication Number WO/2020/092387
Publication Date 07.05.2020
International Application No. PCT/US2019/058591
International Filing Date 29.10.2019
IPC
C12N 15/85 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
C12N 5/078 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/44 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Applicants
  • NANTBIO, INC. [US]/[US]
Inventors
  • GARBAN, Hermes J.
  • NIAZI, Kayvan
Agents
  • FESSENMAIER, Martin
  • PHUKAN, Priti D.
  • DEAN, Ryan S.
  • BALLEW-CHANG, Nicole
Priority Data
62/752,82430.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SELF REPLICATING RNA SYSTEM
(FR) SYSTÈME D'ARN À AUTO-RÉPLICATION
Abstract
(EN)
Compositions, methods and uses of self-replicating RNA molecules that include a recombinant nucleic acid encoding a protein of interest such as a chimeric antigenic receptor or an antibody are presented. The self-replicating RNA molecule are introduced into an immune competent cell such that the chimeric antigenic receptor or the antibody are efficiently expressed in the immune competent cell while increasing the stability of the recombinant nucleic acid in the cell and reducing the potential integration of the recombinant nucleic acid into the genome of the immune competent cell.
(FR)
L'invention concerne des compositions, des procédés et des utilisations de molécules d'ARN à auto-réplication qui comprennent un acide nucléique recombinant codant pour une protéine d'intérêt comme un récepteur antigénique chimérique ou un anticorps. La molécule d'ARN à auto-réplication est introduite dans une cellule immunocompétente de telle sorte que le récepteur antigénique chimérique ou l'anticorps est exprimé efficacement dans la cellule immunocompétente tout en augmentant la stabilité de l'acide nucléique recombinant dans la cellule et en réduisant l'intégration potentielle de l'acide nucléique recombinant dans le génome de la cellule immunocompétente.
Latest bibliographic data on file with the International Bureau